CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
Living with CLL
If you are a veteran, active-duty military, or a care partner and would be interested in joining a CLL Society Support Group for veterans / active-duty military, please complete this brief survey to indicate your interest in participating and help us identify the best time for meeting.
CLL Advocate Network (CLLAN), a global network of CLL patient organizations including CLL Society, surveyed nonprofits around the world to understand what support services and resources are offered to individuals impacted by CLL / SLL. The information collected was used to build a global resource hub. Patients and care partners can access the resource hub for free on the CLLAN website.
Pointers on Doing Your Own CLL Research
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
I Missed It by That Much: CR but No uMRD by 1 per Million
Testing for measurable residual disease (MRD) through next-generation sequencing (NGS) with clonoSEQ revealed zero to one cell per million in the blood.
Caring for the CLL Care Partner
In his book, Dr. Nabhan acknowledges the invaluable role care partners play for their loved ones living with CLL and the toll doing so can have.
CLL is Still in Retreat on My Epcoritamab Trial
I started epcoritamab, a bispecific antibody, in August 2023, and now, entering 2025, I continue to do well in complete remission with low levels of MRD.
WHAT'S NEW IN CLL / SLL
CLL / SLL Expert Healthcare Provider Directory
Having a healthcare provider on your team with expertise in CLL can make a significant difference in your treatment journey. These specialists stay up to date on the latest research and can help ensure you receive the most effective treatment options.
Visit the CLL Society website to learn more about what defines a CLL expert and explore our directory to find one near you today.
ADVOCACY AND POLICY
CLL Society Supports Veterans Benefits Administration’s Interim Final Rule Establishing a Presumptive Service Connection for Leukemia Patients
CLL Society advocated for CLL veterans to the VBA on a presumptive service connection for those exposed to particulate matter and diagnosed with leukemia.
CLL Society Joins the Protecting Innovation in Rare Cancers (PIRC) in Educating CMS About Acalabrutinib and Its Therapeutic Alternatives As Agency Prepares for IRA Negotiations
As Inflation Reduction Act negotiations begin, CLL Society is ensuring CMS understands the importance of treatments for CLL patients and physicians.
CLL Society Responds to Government Report Citing Need to Improve Medicare Advantage Plans
CLL Society joins a growing number of patient advocacy organizations interested in ensuring that the benefits of the recently passed Inflation Reduction Act are not outweighed by the components that cause us concern
UPCOMING EVENTS
Wednesday, March 26, 2025 at 11:30 AM PT / 2:30 PM ET
Join CLL Society for the webinar CLL 101: Biology, Symptoms, and Diagnosis, which will provide a comprehensive introduction to chronic lymphocytic leukemia (CLL). Whether you’re newly diagnosed, have been living with CLL for decades, or supporting a loved one on their journey, this session will cover the key aspects of CLL in an accessible and easy-to-understand format.
Nurse Practitioner Josie Montegaard will present on the basics of CLL, including its biology, the distinction between CLL and SLL, its classification as a chronic disease, symptoms and how it presents, diagnosis and testing, as well as potential causes, including genetic and environmental factors. CLL patient advocate Stephen Feldman will share important resources and help moderate your questions.
The webinar will be geared towards beginners.
On-Demand Replay
If you missed the recent webinar with Dr. Nitin Jain on CLL / SLL research presented at the ASH 2024 conference, you can catch the replay, presentation slides, and transcript here! Watch now!
If you missed the recent webinar with William A. Werbel, MD, PhD, you can watch the full webinar, Common Infections with CLL: Prevention and Treatment.
If you missed the recent Q&A-style Facebook Live event “Ask Me Anything” Featuring Jacqueline Broadway-Duren, PhD, DNP, APRN, FNP-BC, and Doreen Zetterlund, you can catch the replay here!
Treatment Updates
Phase 1 Study of Noncovalent BTK Inhibitor Docirbrutinib
A phase 1 clinical trial is recruiting patients to test the safety and tolerability of the new noncovalent BTK inhibitor docirbrutinib.
A New Trispecific Antibody for CLL on the Horizon
AZD5492 is a novel trispecific that engages mainly CD8+ T cells in the hope of reducing adverse events in CLL compared to bispecific antibodies.
MRD Kinetics of Zanubrutinib-Venetoclax-Obinutuzumab in CLL
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
Equitable Access and Regulatory News
Understanding NCCN Guidelines for CLL / SLL as a Patient
NCCN guidelines are the gold standard where CLL experts recommend best practices. Learn what CLL patients should know about the latest update.
